You just read:

Real-World Study Further Confirms Safety Profile of XARELTO® in Nearly 45,000 People with Non-Valvular Atrial Fibrillation (NVAF), Including Those with Concomitant Diabetes

News provided by

Janssen

02 Apr, 2016, 10:30 ET